^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MTAP deletion

    i
    Other names: MTAP, Methylthioadenosine Phosphorylase, S-Methyl-5'-Thioadenosine Phosphorylase, MSAP, 5’-Methylthioadenosine Phosphorylase, MTA Phosphorylase, MTAPase, C86fus, Epididymis Secretory Sperm Binding Protein, Epididymis Luminal Protein 249, MeSAdo Phosphorylase, HEL-249, DMSMFH, DMSFH, LGMBF, BDMF
    Entrez ID:
    4507
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    8d
    A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer (clinicaltrials.gov)
    P2, N=60, Suspended, M.D. Anderson Cancer Center | Not yet recruiting --> Suspended
    Trial suspension
    |
    MTAP (Methylthioadenosine Phosphorylase)
    |
    MTAP deletion
    |
    gemcitabine • albumin-bound paclitaxel • oxaliplatin • irinotecan • navlimetostat (BMS‐986504)
    10d
    Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss (clinicaltrials.gov)
    P1, N=36, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting | Initiation date: Jun 2026 --> Feb 2026
    Enrollment open • Trial initiation date
    |
    MTAP (Methylthioadenosine Phosphorylase)
    |
    MTAP deletion
    |
    Lynparza (olaparib) • navlimetostat (BMS‐986504)
    10d
    Journey of Methionine Adenosyltransferase 2A Inhibitors: From Bench to Advanced Clinical Trials. (PubMed, J Med Chem)
    Here, we trace the evolution of MAT2A inhibitors from early substrate-competitive molecules to allosteric inhibitors now in clinical evaluation. We discuss the design of next-generation inhibitors with improved potency, selectivity, and pharmacokinetic properties, including central nervous system penetration.
    Review • Journal
    |
    MTAP (Methylthioadenosine Phosphorylase) • MAT2A (Methionine Adenosyltransferase 2A)
    |
    MTAP deletion
    18d
    CL1-95035-001: A study of S095035 as a single agent and in combination in adult participants with advanced or metastatic solid tumors with deletion of MTAP (2025-521249-25-00)
    P1/2, N=118, Recruiting, Institut De Recherches Internationales Servier IRIS
    New P1/2 trial
    |
    MTAP (Methylthioadenosine Phosphorylase)
    |
    MTAP deletion • IDH wild-type
    |
    vopimetostat (TNG462)
    18d
    CA240-0029: A Study of BMS-986504 in Combination with Pembrolizumab Plus Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer with Homozygous MTAP Deletion (2025-521511-40-00)
    P2/3, N=191, Recruiting, Bristol-Myers Squibb Services Unlimited Company
    New P2/3 trial
    |
    MTAP (Methylthioadenosine Phosphorylase)
    |
    MTAP deletion
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • paclitaxel • albumin-bound paclitaxel • pemetrexed • navlimetostat (BMS‐986504)
    18d
    A first-in-human study to learn how safe BAY 3713372 is and how it works in participants with MTAP-deleted solid tumors (2025-520623-24-00)
    P1/2, N=195, Recruiting, Bayer AG
    New P1/2 trial • First-in-human
    |
    MTAP (Methylthioadenosine Phosphorylase)
    |
    MTAP deletion
    18d
    CA240-0030: A study of BMS-986504 in combination with Nab-p/Gem versus placebo in combination with Nab-p/Gem in untreated metastatic PDAC with homozygous MTAP deletion (2025-522598-12-00)
    P2/3, N=162, Recruiting, Bristol-Myers Squibb Services Unlimited Company
    New P2/3 trial
    |
    MTAP (Methylthioadenosine Phosphorylase)
    |
    MTAP deletion
    |
    gemcitabine • albumin-bound paclitaxel • navlimetostat (BMS‐986504)
    22d
    A Study of PEP08 in Patients With MTAP-Del Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=40, Recruiting, PharmaEngine | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    |
    MTAP (Methylthioadenosine Phosphorylase)
    |
    MTAP deletion
    29d
    Prevalence and Actionability of MTAP Loss in Oncogene-Driven Lung Cancer. (PubMed, bioRxiv)
    PRMT5 inhibitor activity is independent of TKI exposure, driver alteration, and SDMA expression and enhanced by addition of TKI. These findings support clinical evaluation of PRMT5 inhibitor + TKI combinations for advanced NSCLC.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • MTAP (Methylthioadenosine Phosphorylase)
    |
    KRAS mutation • EGFR mutation • ALK rearrangement • MTAP deletion
    29d
    Case Report: IGFBP5-ALK fusion-positive case of high-grade endometrial stromal sarcoma with response to ALK-targeted therapy. (PubMed, Front Oncol)
    After failure of gemcitabine/docetaxel chemotherapy, next-generation sequencing identified an IGFBP5-ALK fusion (breakpoint: IGFBP5 exon 1 - ALK exon 19), a TERT promoter mutation, and a homozygous CDKN2A/CDKN2B/MTAP deletion. This case highlights the first documented response to an ALK inhibitor in ALK-rearranged HG-ESS. The findings underscore the importance of comprehensive molecular profiling in identifying targetable alterations in rare sarcomas and support the use of iruplinalkib as an effective therapeutic option in this setting.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • TERT (Telomerase Reverse Transcriptase) • MTAP (Methylthioadenosine Phosphorylase) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • BCOR (BCL6 Corepressor) • IGFBP5 (Insulin Like Growth Factor Binding Protein 5)
    |
    ALK positive • ALK rearrangement • ALK fusion • CDKN2A deletion • MTAP deletion
    |
    gemcitabine • docetaxel • Qi Xinke (iruplinalkib)
    1m
    Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss (clinicaltrials.gov)
    P1, N=36, Not yet recruiting, M.D. Anderson Cancer Center
    New P1 trial
    |
    MTAP (Methylthioadenosine Phosphorylase)
    |
    MTAP deletion
    |
    Lynparza (olaparib) • navlimetostat (BMS‐986504)
    2ms
    A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=260, Recruiting, IDEAYA Biosciences | Not yet recruiting --> Recruiting
    Enrollment open
    |
    MTAP (Methylthioadenosine Phosphorylase)
    |
    MTAP deletion
    |
    IDE397